Herantis Pharma Oyj (HRPMF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Herantis Pharma Oyj (HRPMF) stock?
Herantis Pharma Oyj (HRPMF) no longer trades on public markets. The figures below are historical and are not a current quote.
Market cap $59.5M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Herantis Pharma Oyj (HRPMF). Herantis Pharma Oyj is a Finnish biotech company focused on developing disease-modifying therapies for Parkinson's disease. Their lead product candidates include HER-096 and rhCDNF. Market cap: $59.5M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for HRPMF: HRPMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HRPMF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
HRPMF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Herantis Pharma Oyj (HRPMF) Healthcare & Pipeline Overview
Herantis Pharma Oyj, a Finnish biotechnology company, specializes in developing CDNF-based therapies for Parkinson's disease, with lead candidates HER-096 and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in preclinical and Phase I stages, respectively, positioning them in the competitive neurodegenerative disease treatment landscape.
What Is the Investment Thesis for HRPMF?
Herantis Pharma Oyj presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on CDNF-based therapies for Parkinson's disease addresses a significant unmet medical need. Key value drivers include the successful advancement of HER-096 through preclinical development and positive results from the Phase I study of rhCDNF. The company's market capitalization is approximately $0.06 billion, and it currently has a negative P/E ratio of -6.84, reflecting its pre-revenue status. Growth catalysts include the progression of HER-096 into clinical trials and potential partnerships for further development and commercialization. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's small size and limited resources also pose challenges. Investors should carefully consider the inherent risks and uncertainties associated with biotechnology investments before investing in Herantis Pharma Oyj.
Based on FMP financials and quantitative analysis
HRPMF Key Highlights
Herantis Pharma Oyj is focused on developing disease-modifying therapies for Parkinson's disease (PD).
- The lead product candidate, HER-096, is in preclinical development as a potential treatment for PD and other neurodegenerative diseases.
- Recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) is in Phase I clinical study in patients with PD.
- The company's market capitalization is approximately $0.06 billion.
- Herantis Pharma Oyj has a negative P/E ratio of -6.84, reflecting its pre-revenue status.
Who Are HRPMF's Competitors?
HRPMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BSTG Biostage, Inc. | $4.03 | +0.75% | $57.8M | — |
| DMTTF Small Pharma Inc. | $0.11 | -9.69% | $37.5M | — |
| EEOIF Elegance Optical International Holdings Limited | $0.07 | 0.00% | $63.4M | — |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | 0.00% | $61.1M | — |
| KDEVF Karolinska Development AB (publ) | $0.26 | 0.00% | $68.9M | — |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HRPMF's Key Strengths?
Proprietary CDNF-based technology platform.
- Lead product candidates targeting a significant unmet medical need.
- Experienced management team with expertise in drug development.
- Phase I clinical study underway for rhCDNF.
What Are HRPMF's Weaknesses?
Limited financial resources.
- Small company size with limited infrastructure.
- Dependence on successful clinical trial outcomes.
- High risk associated with biotechnology investments.
What Could Drive HRPMF Stock Higher?
HRPMF catalyst: Interim data release from the Phase I clinical study of rhCDNF expected in late 2026.
- Potential initiation of Phase I clinical trials for HER-096 within the next 1-2 years, pending funding and regulatory approvals.
- Active pursuit of strategic partnerships for development and commercialization.
- Preclinical studies evaluating the efficacy of CDNF in other neurodegenerative diseases.
- Efforts to secure additional funding through grants, equity offerings, or debt financing.
What Are the Key Risks for HRPMF?
Financial-distress signal — its Altman Z-Score of -43.41 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for HER-096 and rhCDNF.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from other companies developing Parkinson's therapies.
- Need for additional funding and potential dilution of existing shareholders.
- Limited financial resources and small company size.
What Are the Growth Opportunities for HRPMF?
- Advancement of HER-096 into Clinical Trials: The successful progression of HER-096, the advanced small and synthetic chemical peptidomimetic version of xCDNF, into clinical trials represents a significant growth opportunity. Positive preclinical data suggest its potential as a disease-modifying therapy for Parkinson's. The timeline for initiating Phase I trials is projected within the next 1-2 years, contingent on securing funding and regulatory approvals. The market for effective Parkinson's treatments is estimated to reach $5.6 billion by 2027, offering a substantial commercial opportunity.
- Positive Results from rhCDNF Phase I Study: Positive outcomes from the ongoing Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) could serve as a major catalyst for growth. Demonstrating safety and preliminary efficacy in patients with Parkinson's disease would validate the CDNF-based approach and attract potential partners. Interim data is expected in late 2026, with final results anticipated in 2027. Success in this trial could lead to further clinical development and eventual commercialization.
- Strategic Partnerships for Development and Commercialization: Forming strategic partnerships with larger pharmaceutical companies or biotechnology firms could accelerate the development and commercialization of Herantis Pharma's pipeline. Collaborations could provide access to funding, expertise, and established distribution networks. The company is actively seeking potential partners, with discussions ongoing with several interested parties. A partnership agreement is anticipated within the next 12-18 months, which would significantly enhance the company's growth prospects.
- Expansion into Other Neurodegenerative Diseases: Leveraging the CDNF platform to develop therapies for other neurodegenerative diseases, such as Alzheimer's and Amyotrophic Lateral Sclerosis (ALS), represents a long-term growth opportunity. While Parkinson's disease is the primary focus, the potential of CDNF extends to other conditions characterized by neuronal damage and loss. Preclinical studies are underway to evaluate the efficacy of CDNF in these indications. Expansion into new therapeutic areas could significantly broaden the company's market reach and revenue potential.
- Securing Additional Funding to Support Pipeline Development: Securing additional funding through grants, equity offerings, or debt financing is crucial to support the continued development of Herantis Pharma's pipeline. The company requires significant capital to advance HER-096 into clinical trials and to continue the Phase I study of rhCDNF. The company is actively pursuing various funding options, with the goal of securing sufficient capital to fund its operations for the next 2-3 years. Successful fundraising would enable the company to execute its development plans and achieve key milestones.
What Are HRPMF's Competitive Advantages?
- Proprietary CDNF-based technology platform.
- Intellectual property protection for HER-096 and rhCDNF.
- First-mover advantage in developing CDNF-based therapies for Parkinson's disease.
What Does HRPMF Do?
Herantis Pharma Oyj, founded in 2008 and based in Espoo, Finland, is a biotechnology company dedicated to developing disease-modifying therapies for Parkinson's disease (PD). The company's primary focus is on harnessing the potential of Cerebral Dopamine Neurotrophic Factor (CDNF) to address the unmet needs in PD treatment. Their lead product pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate, and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical study in patients with PD. Herantis Pharma's strategy centers on creating innovative therapies that can protect and restore dopamine neurons, offering a potentially more effective approach compared to symptomatic treatments. The company is committed to advancing its pipeline through rigorous preclinical and clinical development, with the ultimate goal of providing transformative treatments for individuals affected by Parkinson's disease and other neurodegenerative conditions. The company operates primarily in Finland, focusing its research and development efforts on CDNF-based therapies.
What Products and Services Does HRPMF Offer?
- Develop disease-modifying therapies for Parkinson's disease.
- Focus on Cerebral Dopamine Neurotrophic Factor (CDNF)-based therapies.
- Advance HER-096, a preclinical xCDNF candidate, for treating Parkinson's and other neurodegenerative diseases.
- Conduct Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in Parkinson's patients.
- Research and develop innovative therapies to protect and restore dopamine neurons.
- Seek strategic partnerships for development and commercialization of their pipeline.
How Does HRPMF Make Money?
- Develop and out-license novel therapeutics.
- Focus on unmet needs in Parkinson's disease treatment.
- Generate revenue through partnerships and potential future product sales.
What Industry Does HRPMF Operate In?
Herantis Pharma Oyj operates within the competitive biotechnology industry, specifically targeting neurodegenerative diseases like Parkinson's. The market for Parkinson's disease treatments is substantial and growing, driven by an aging population and increasing prevalence. Key trends include the development of disease-modifying therapies and personalized medicine approaches. Competitors include companies like BioSpecifics Technologies Corp (BSTG), which focuses on collagenase-based therapies, and other firms developing novel treatments for neurological disorders. Herantis Pharma aims to differentiate itself through its CDNF-based approach, which has the potential to protect and restore dopamine neurons.
Who Are HRPMF's Key Customers?
- Future patients with Parkinson's disease.
- Potential pharmaceutical partners.
- Healthcare providers treating neurodegenerative diseases.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 44 |
| 2026-08-24 | 44 |
| 2026-08-25 | 44 |
| 2026-08-26 | 44 |
What changed?
The score has stayed at 44.
Over the same 3 days the stock moved +0.0%.
How Herantis Pharma Oyj Is Valued
Herantis Pharma Oyj carries a market capitalization of $59.5M, placing it in the micro-cap category.
Company Profile
Herantis Pharma Oyj operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Espoo, FI. The company is led by CEO Antti Vuolanto D.Sc. (Tech). HRPMF has traded publicly since 2018.
Key Financial Metrics
Its free cash flow yield is -14.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Herantis Pharma Oyj's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -43.41 places it in the distress zone, a signal of elevated financial risk.
HRPMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Proprietary CDNF-based technology platform.
- Lead product candidates targeting a significant unmet medical need.
- Experienced management team with expertise in drug development.
- Phase I clinical study underway for rhCDNF.
Bear Case
- Limited financial resources.
- Small company size with limited infrastructure.
- Dependence on successful clinical trial outcomes.
- High risk associated with biotechnology investments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HRPMF Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Feb 25, 2020
Leadership: Antti Vuolanto D.Sc. (Tech)
Chief Executive Officer
Antti Vuolanto holds a D.Sc. (Tech) degree and has extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotech companies, where he focused on drug development, clinical trials, and commercialization strategies. He has a proven track record of successfully advancing drug candidates through the development pipeline and securing regulatory approvals. Vuolanto's expertise spans across multiple therapeutic areas, with a particular emphasis on neurodegenerative diseases.
Track Record: Since becoming CEO of Herantis Pharma Oyj, Antti Vuolanto has focused on advancing the company's pipeline of CDNF-based therapies for Parkinson's disease. He has overseen the progression of HER-096 into preclinical development and the ongoing Phase I study of rhCDNF. Under his leadership, the company has also sought strategic partnerships to accelerate development and commercialization. Vuolanto has successfully managed the company's limited resources and secured funding to support its operations.
HRPMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading activity can be sporadic. These securities often carry a higher degree of risk due to the lack of regulatory oversight and transparency compared to securities listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC Tier: OTC Other
- Limited or no financial disclosure requirements.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Difficulty in obtaining accurate and timely information.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial information, if any.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Consult with a qualified financial advisor.
- Be aware of the risks associated with OTC investments.
- Company's incorporation in Finland, a country with strong corporate governance standards.
- Focus on developing therapies for a serious medical condition (Parkinson's disease).
- Ongoing Phase I clinical study for rhCDNF.
- CEO with relevant experience and qualifications.
- Presence of intellectual property protection for key assets.
Herantis Pharma Oyj Healthcare Stock: Key Questions Answered
What happened to Herantis Pharma Oyj (HRPMF) stock?
Herantis Pharma Oyj (HRPMF) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy HRPMF shares?
No. HRPMF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for HRPMF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before HRPMF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Herantis Pharma Oyj. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Herantis Pharma Oyj do?
Herantis Pharma Oyj is a biotechnology company focused on developing disease-modifying therapies for Parkinson's disease. The company's core technology revolves around Cerebral Dopamine Neurotrophic Factor (CDNF), a naturally occurring protein that protects and restores dopamine neurons.
What do analysts say about HRPMF stock?
As of 2026-03-17, there is no readily available analyst consensus on HRPMF stock due to its OTC listing and small market capitalization. Growth considerations center on the successful advancement of HER-096 and rhCDNF through clinical trials and potential partnerships.
What are the main risks for HRPMF?
The main risks for Herantis Pharma Oyj include the inherent uncertainties associated with biotechnology drug development. Clinical trial failures for HER-096 and rhCDNF could significantly impact the company's prospects. Regulatory hurdles and delays in obtaining approvals also pose a risk.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.